TEL AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage ...

SciSparc (SPRC)announced that MitoCareX Bio, its joint venture with Dr. Alon Silberman, is expanding its research and ...

More than 66,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.

AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Pancreatic Ductal Carcinoma.

Life without a pancreas involves treatments to replace organ function. Learn how different surgical techniques affect overall ...

Autologous SUPLEXA is under clinical development by Alloplex Biotherapeutics and currently in Phase I for Pancreatic Cancer.

In a compelling episode of "," Dr. John Marshall engages in a profound dialogue with Julie Fleshman, a vanguard in the realm ...

EDAP TMS (EDAP) announced that the first patient has been treated in a phase I/II PULS Trial sponsored by the Centre Leon Berard, Lyon, France, ...

pancreatic cancer represents a common target for pharmaceutical companies. Newer agents are in development with the promise of further refinement in treatment selection based on molecular tumor ...

Analyst Ami Fadia of Needham maintained a Buy rating on Immuneering (IMRX – Research Report), retaining the price target of $15.00.Stay Ahead ...

SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies ...